Skip to Main Content (Press Enter)

Logo UNIBS
  • ×
  • Home
  • People
  • Organizations
  • Expertise & Skills
  • Outputs
  • Jobs
  • Degrees
  • Courses
  • Third Mission

Expertise & Skills
Logo UNIBS

|

Expertise & Skills

unibs.it
  • ×
  • Home
  • People
  • Organizations
  • Expertise & Skills
  • Outputs
  • Jobs
  • Degrees
  • Courses
  • Third Mission
  1. Outputs

Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group

Academic Article
Publication Date:
2019
Abstract:
Introduction: Patients with late-onset Pompe disease (LOPD) receiving enzyme replacement therapy (ERT) may develop IgG antibodies against alglucosidase alpha (anti-rhGAA) in the first 3 months of treatment. The exact role of these antibodies in modulating efficacy of ERT in this group of patients is still not fully understood. To assess whether anti rh-GAA antibodies interfere with ERT efficacy, we studied a large Italian cohort of LOPD patients. Methods: We analyzed clinical findings and performed serial measurements of IgG anti rh-GAA antibody titers from 64 LOPD patients treated with ERT. The first examination (T0) was completed on average at 17.56 months after starting ERT, while the follow-up (T1) was collected on average at 38.5 months. Differences in T0–T1 delta of the six-minute walking test (6MWT), MRC sum score (MRC), gait, stairs and chair performance (GSGC) and forced vital capacity (FVC) were considered and then related to the antibody titers. Results: Almost 22% of the patients never developed antibodies against GAA, while 78.1% had a positive titer (31.2% patients developed a low titer, 43.8% a medium titer and 3.1% a high titer). No statistical significance was found in relating the T0–T1 delta differences and antibody titers, except for MRC sum score values in a subgroup of patients treated < 36 months, in which those with a null antibody titer showed a greater clinical improvement than patients with a positive titer. Conclusion: Our results confirm that in a large cohort of LOPD patients, anti rh-GAA antibody generation did not significantly affect either clinical outcome or ERT efficacy. However, in the first 36 months of treatment, a possible interference of low-medium antibody titers with the clinical status could be present. Therefore, a careful and regular evaluation of antibody titers, especially in cases with evidence of clinical decline despite ERT, should be performed.
CRIS type:
1.1 Articolo in rivista
Keywords:
Anti rh-GAA antibodies; Glycogen storage diseases II; GSD II; LOPD; Pompe disease
List of contributors:
Filosto, M.; Cotti Piccinelli, S.; Ravaglia, S.; Servidei, S.; Moggio, M.; Musumeci, O.; Donati, M. A.; Pegoraro, E.; Di Muzio, A.; Maggi, L.; Tonin, P.; Marrosu, G.; Sancricca, C.; Lerario, A.; Sacchini, M.; Semplicini, C.; Bozzoni, V.; Telese, R.; Bonanno, S.; Piras, R.; Maioli, M. A.; Ricci, G.; Vercelli, L.; Galvagni, A.; Gallo Cassarino, S.; Caria, F.; Mongini, T.; Siciliano, G.; Padovani, A.; Toscano, A.
Authors of the University:
Center for Neuromuscular Diseases
FILOSTO MASSIMILIANO
PADOVANI ALESSANDRO
Handle:
https://iris.unibs.it/handle/11379/535300
Published in:
ADVANCES IN THERAPY
Journal
  • Support
  • Privacy
  • Use of cookies
  • Legal notes

Powered by VIVO | Designed by Cineca | 26.5.1.0